Patrick Y. Lu is Founder, President, and CEO of Sirnaomics, a biopharmaceutical company developing RNA-based therapeutics. With more than 25 years in nucleic acid drug development across both major pharmaceutical companies and startups, he has grown Sirnaomics from an early-stage venture into a publicly traded, internationally recognized company, raising roughly $340 million in funding along the way.
Lu has guided the company's pipeline of siRNA therapeutic candidates targeting cancer, fibrosis, and metabolic disease, built around two proprietary delivery platforms: polypeptide nanoparticle formulations and GalNAc-based conjugation. Under his direction, Sirnaomics reported Phase II trial results showing a complete response rate in treating basal cell carcinoma.
As an entrepreneur, Lu emphasizes choosing the right therapeutic targets, using efficient delivery systems, and matching treatments to the clinical indications where they are most likely to succeed, principles he applies to building teams capable of turning scientific research into approved treatments.
